2020
DOI: 10.21203/rs.3.rs-65437/v1
|View full text |Cite
Preprint
|
Sign up to set email alerts
|

Comparison of Pancreatic Cancer Treatment Outcomes: A Real-World Data Analysis

Abstract: Background Since the ground-breaking phase III MPACT trial showed clear benefit of gemcitabine-nab-paclitaxel, this regimen has emerged as the standard of care for advanced pancreatic adenocarcinoma (PAC). Prior to this study, few studies have shown how results from randomized controlled trial translate to the real world. This study investigated how patients fared in the real world. Methods This single-centre, retrospective study was conducted in the Vaasa Central Hospital, Finland. 148 patients with PAC (IC… Show more

Help me understand this report
View published versions

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals

citations
Cited by 0 publications
references
References 37 publications
(54 reference statements)
0
0
0
Order By: Relevance

No citations

Set email alert for when this publication receives citations?